Brainsway

Company Overview

Snapshot

Founded in January 2003 by Avner Hagai, Yiftach Roth, David Zacut, and Abraham Zangen, Brainsway operates with 51–200 employees. The company has raised a total of $79.95 million across 6 funding rounds from 6 investors. In September 2024, Brainsway announced a US$20 million private placement with Valor Equity Partners.

Business overview

Brainsway develops advanced noninvasive neurostimulation treatments for mental health disorders, leveraging its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology. The company's core technology is based on patents filed by the US National Institutes of Health (NIH) and by Brainsway itself, holding an exclusive license from the NIH for the patent and its technology. Brainsway's solutions are FDA cleared for treating major depressive disorder, obsessive-compulsive disorder (OCD), and smoking addiction, and are approved in Canada for major depressive disorder. The company also holds CE Mark clearance outside North America for various psychiatric and neurological conditions, including post-traumatic stress disorder and Alzheimer's disease. Brainsway serves markets globally, collaborating with scientists and academic research institutions on clinical trials for neuropsychiatric and neuroscience applications.

Strategic signal

In September 2024, BrainsWay announced a significant expansion on the U.S. East Coast, indicating a strategic push to broaden its market presence and accessibility for its Deep TMS™ treatments. This move signals to investors a focused effort on scaling operations and increasing patient reach within a key geographical market, potentially driving future revenue growth and market share.

Company Intelligence Q&A

What was a significant recent financial event for Brainsway?

In September 2024, Brainsway announced a US$20 million private placement with Valor Equity Partners.

What recent regulatory milestone did Brainsway achieve for its Deep TMS technology?

In September 2025, BrainsWay received FDA clearance for an accelerated Deep TMS protocol for the non-invasive treatment of Major Depressive Disorder (MDD).

How is Brainsway expanding its market reach in East Asia?

In October 2024, BrainsWay further penetrated East Asia with the placement of 15 additional Deep TMS™ systems in Taiwan and South Korea.

What strategic partnership did Brainsway forge in the Northeast U.S.?

In September 2023, BrainsWay forged a strategic partnership with a treatment provider in the Northeast U.S. to expand access to its therapies.

What is Brainsway's current status regarding public markets?

Brainsway became Public on TASE in January 2007 and Public on NASDAQ in April 2019.